The Company is a bio-dressing made of live, medical-grade maggots, is used by private and public hospitals in Singapore and Hong Kong to disinfect and debride chronic wounds, known as Maggot Debridement Therapy.. It is a Singapore-based MedTech company that specializes in the development of products to treat chronic wounds.
The Company product is clinically proven to reduce amputation rates and eliminate infections in chronic wounds, especially diabetic foot ulcers and pressure ulcers.
The Company is also developing collagen wound dressing products from bullfrog skin, which has shown promising results in its ability to heal wounds.
The Company currently operates in the following two reporting segments: Maggot Debridement Therapy Product and Cosmeceutical Product.
HISTORY
2019 The Company began its operations in Singapore.
2023 The Company is an exempted company incorporated on 22 September, 2023 under the laws of the Cayman Islands.
2024 The Company completion of the reorganization in January 2024.
2025: The Ordinary Shares have been listed on the Nasdaq Capital Markets since April 10, 2025 under the symbol “CUPR.”
Headquarters
Blk 1090 Lower Delta Road 06-08
Singapore; Singapore;
Postal Code: 169201
Contact Details: Purchase the Cuprina Holdings (Cayman) Ltd. report to view the information.
Website: http://www.cuprina.com.sg
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service